azacitidine has been researched along with Chromosome Deletion in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (6.82) | 18.7374 |
| 1990's | 4 (9.09) | 18.2507 |
| 2000's | 9 (20.45) | 29.6817 |
| 2010's | 22 (50.00) | 24.3611 |
| 2020's | 6 (13.64) | 2.80 |
| Authors | Studies |
|---|---|
| Abbas, HA; Al-Atrash, G; Alaniz, Z; Allison, JP; Barrodia, P; Basu, S; Beird, HC; Daver, N; Ding, M; Futreal, A; Garcia-Manero, G; Green, MR; Hao, D; Im, JS; Konopleva, M; Kornblau, SM; Little, L; Lu, W; Marques-Piubelli, ML; Mathews, JT; Ning, J; Parra, ER; Rai, K; Reville, PK; Sharma, P; Solis, LM; Takahashi, K; Tamegnon, A; Tomczak, K; Wang, F; Wang, L; Wang, R; Wang, W; Zhang, J | 1 |
| Bernard, E; Cavelier, L; Dybedal, I; Ebeling, F; Ejerblad, E; Flogegård, M; Garelius, H; Göhring, G; Grønbaek, K; Hellström-Lindberg, E; Jädersten, M; Kittang, AO; Lorenz, F; Marcher, CW; Möllgård, L; Nilsson, L; Nørgaard, JM; Öster Fernström, A; Papaemmanuil, E; Rasmussen, B; Saft, L; Tobiasson, M | 1 |
| De Moerloose, B; Decaluwe, W; Flotho, C; Hofmans, M; Lammens, T; Niemeyer, C; Philippé, J; Schröder, R; Van Roy, N | 1 |
| Amat, P; Calabuig, M; Chaves, FJ; Fuentes, A; García, F; Hernández-Boluda, JC; Martín, I; Navarro, B; Orts, M; Seda, E; Serrano, A; Solano, C; Tormo, M; Villamón, E; Yagüe, N | 1 |
| Abbott, LS; Cada, M; Dror, Y; Johnston, DL; Klaassen, RJ; Leung, EW; Schechter, T; Shabanova, I | 1 |
| Endo, S; Fukao, T; Hama, A; Kadowaki, T; Kojima, S; Muramatsu, H; Nozawa, A; Ohnishi, H; Ozeki, M; Takahashi, Y; Yasue, S | 1 |
| Angelopoulou, MK; Chatzidimitriou, C; Konstantopoulos, K; Korkolopoulou, P; Lafioniatis, S; Lakiotaki, E; Pappa, V; Plata, E; Vassilakopoulos, TP | 1 |
| Balleari, E; Bernal, T; Beyne-Rauzy, O; Bordessoule, D; Calabuig, M; Cametti, G; Campelo, MD; Cheze, S; Cony-Makhoul, P; Dreyfus, F; Fenaux, P; Fensterl, J; Ferrero, D; Gaidano, G; Germing, U; Gioia, D; Götze, K; Guerci-Bresler, A; Hamel, JF; Kaivers, J; Kelaidi, C; Komrokji, R; Kotsianidis, I; Müller-Thomas, C; Pane, F; Park, S; Ramos, F; Roboz, GJ; Rose, C; Sanna, A; Santini, V; Sanz, GF; Sapena, R; Sekeres, MA; Stamatoullas, A; Steensma, DP; Thépot, S; Toma, A; Vey, N; Wattel, E | 1 |
| Nohgawa, M; Oka, S; Ono, K | 1 |
| Bailen, A; Calderon, C; Casaño, FJ; Falantes, J; Hermosin, L; Hernandez-Mohedo, F; Hernández-Rivas, JM; Hernandez-Sanchez, JM; Labrador, M; Lumbreras, E; Medina Perez, A; Sanchez-Garcia, J; Serrano, J; Solé Rodriguez, M; Torres-Sabariego, A; Vahí, M | 1 |
| Fisher, KE; Gaikwad, AS; Hashmi, SK; Loh, ML; Lopez-Terrada, DH; Marcogliese, AN; Niemeyer, CM; Punia, JN; Rao, P; Rau, RE; Ringrose, J; Roy, A | 1 |
| Ichikawa, M; Iizuka, H; Kurokawa, M; Masuda, A; Nannya, Y; Yamamoto, G; Yatomi, Y; Yoshimi, A | 1 |
| Gore, SD; Komrokji, RS; Zeidan, AM | 1 |
| Honda, H; Inaba, T; Nagamachi, A | 1 |
| Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Takakuwa, T | 1 |
| Becker, N; Effenberger, K; Esteller, M; Hagmann, W; Izbicki, JR; Kemming, D; Kim, SZ; Lamszus, K; Pantel, K; Riethdorf, S; Risch, A; Sandoval, J; Uzunoglu, FG; Westphal, M; Wikman, H; Wrage, M | 1 |
| Jaksic, O; Kusec, R; Lasan-Trcic, R; Lucijanic, M; Pejsa, V; Stoos-Veic, T | 1 |
| Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM | 1 |
| Dai, Y; He, HS; Huang, DP; Huang, LQ; Jiang, YZ; Su, GP; Sun, ZM | 1 |
| Kato, W; Koga, Y; Nakashima, K; Oba, U; Ono, H; Takada, H | 1 |
| Dimitriou, M; Doolittle, H; Douagi, I; Hellström-Lindberg, E; Jacobsen, SE; Karimi, M; Mortera-Blanco, T; Papaemmanuil, E; Wedge, DC; Woll, PS | 1 |
| Ando, T; Kimura, S; Kizuka, H; Kojima, K; Kubota, Y; Kusaba, K; Nishioka, A; Sano, H; Shindo, T; Ureshino, H | 1 |
| Kotoula, V; Papaioannou, M; Sapalidis, K | 1 |
| Basile, FG | 1 |
| Stone, RM | 1 |
| Chin, K; Chua, CL; Eu, KW; Gray, JW; Ho, YM; Hong, GS; Kuo, WL; Lee, AS; Lie, DK; Ong, DC; Rudduck, C; Seow-Choen, F; Tan, PH; Wong, CY | 1 |
| Sekeres, MA | 1 |
| Leary, C; Lowery-Nordberg, M; Stephens, J; Turturro, F; Veillon, D | 1 |
| Hofmann, WK; Nolte, F | 1 |
| Sanchez, JF | 1 |
| Adès, L; Beyne-Rauzy, O; Boehrer, S; Dreyfus, F; Eclache, V; Fenaux, P; Gardin, C; Itzykson, R; Quesnel, B; Recher, C; Thépot, S; Turlure, P; Vey, N | 1 |
| Czepulkowski, B; Gäken, J; Ireland, R; Krishnamurthy, P; Kulasekararaj, AG; Lea, NC; Marsh, JC; Mian, SA; Mohamedali, AM; Mufti, GJ; Pennaneach, C; Pomplun, S; Smith, AE | 1 |
| Bornhäuser, M; Braulke, F; Bug, G; Ehninger, G; Germing, U; Giagounidis, A; Götze, K; Haase, D; Hofmann, WK; Kündgen, A; Naumann, R; Neesen, J; Platzbecker, U; Röllig, C; Schönefeldt, C; Shirneshan, K; Wermke, M | 1 |
| Haas, PS; Lübbert, M; Verhoef, G; Wijermans, P | 1 |
| Cohn, SL; Cornell, J; McArdle, L; Nair, PN; Stallings, RL | 1 |
| Carén, H; Ejeskär, K; Fransson, S; Kogner, P; Martinsson, T | 1 |
| Brouet, JC; Dellagi, K; Lenoir, GM; Portier, MM | 1 |
| Abatecola, M; Cozzi, R; de Capoa, A; Giancotti, P; Grappelli, C; Perticone, P; Poggesi, I | 1 |
| Baylin, SB; Bova, GS; Cairns, P; Ewing, CM; Herman, JG; Isaacs, WB; Jarrard, DF; Nguyen, SH; Pin, SS; Sidransky, D | 1 |
| Ehrlich, M; Frady, A; Hernandez, R; Varela, M; Zhang, XY | 1 |
| Crichton, DN; Hupp, TR; Kernohan, N; McDowell, HE; Nicoll, G; Thompson, AM | 1 |
| De Greve, H; Hernalsteens, JP; Renckens, S; Van Montagu, M | 1 |
| Karlsson, S; Nienhuis, AW | 1 |
| Osgood, CJ; Seward, SM | 1 |
8 review(s) available for azacitidine and Chromosome Deletion
| Article | Year |
|---|---|
-7/7q- syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; Gene Expression Regulation, Neoplastic; Genetic Association Studies; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Myeloid Cells; Prognosis | 2015 |
Effect of Decitabine Combined with Unrelated Cord Blood Transplantation in an Adult Patient with -7/EVI1+ Acute Myeloid Leukemia: a Case Report and Literature Review.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Decitabine; DNA-Binding Proteins; Fetal Blood; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; MDS1 and EVI1 Complex Locus Protein; Proto-Oncogenes; Transcription Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
5q- syndrome-like features as the first manifestation of myelodysplastic syndrome in a patient with an unbalanced whole-arm translocation der(5;19)(p10;q10).
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Chromosome Aberrations; Chromosome Deletion; Chromosomes, Human, Pair 19; Chromosomes, Human, Pair 5; Fatal Outcome; Female; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide; Translocation, Genetic | 2017 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
Treatment of MDS: something old, something new, something borrowed...
Topics: Azacitidine; Benzoates; Blood Transfusion; Bone Marrow Diseases; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Decitabine; DNA-Cytosine Methylases; Glutathione; Hematinics; Humans; Hydrazines; Immunologic Factors; Lenalidomide; Myelodysplastic Syndromes; Pyrazoles; Randomized Controlled Trials as Topic; Receptors, Fc; Recombinant Fusion Proteins; Risk; Thalidomide; Thrombopoietin | 2009 |
[Current treatment options for myelodysplastic syndromes].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Azacitidine; Blood Transfusion; Bone Marrow Transplantation; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Humans; Iron Overload; Lenalidomide; Leukemia, Myeloid, Acute; Long-Term Care; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Thalidomide | 2010 |
Treatment of myelodysplastic syndromes in elderly patients.
Topics: Aged; Anemia, Macrocytic; Antineoplastic Agents; Azacitidine; Blood Component Transfusion; Case Management; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Contraindications; Hematinics; Hematopoietic Stem Cell Transplantation; Histocompatibility; Humans; Immunomodulation; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Palliative Care; Quality of Life; Risk Assessment; Survival Rate; Thalidomide | 2011 |
Developmental regulation of human globin genes.
Topics: Azacitidine; Chromatin; Chromosome Deletion; Chromosomes, Human, 16-18; Chromosomes, Human, 6-12 and X; Enhancer Elements, Genetic; Fetal Hemoglobin; Gene Expression Regulation; Genes; Globins; Hemoglobins; Humans; Methylation; Mutation; Poly A; Promoter Regions, Genetic; Protein Biosynthesis; Repetitive Sequences, Nucleic Acid; RNA Caps; RNA Processing, Post-Transcriptional; RNA, Messenger; Thalassemia; Transcription Factors | 1985 |
5 trial(s) available for azacitidine and Chromosome Deletion
| Article | Year |
|---|---|
"Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)".
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Karyotype; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes | 2022 |
Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine.
Topics: Aged; Aged, 80 and over; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Cyclin-Dependent Kinase Inhibitor p15; Disease-Free Survival; DNA Methylation; DNA, Neoplasm; Female; GTPase-Activating Proteins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Nucleophosmin; Promoter Regions, Genetic; Survival Rate; Tumor Suppressor Proteins | 2020 |
Prospective randomized trial of 5 days azacitidine versus supportive care in patients with lower-risk myelodysplastic syndromes without 5q deletion and transfusion-dependent anemia.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Female; Follow-Up Studies; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Prognosis; Prospective Studies; Survival Rate | 2018 |
Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Lenalidomide; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Thalidomide | 2013 |
Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosomal Instability; Chromosome Deletion; Cytogenetic Analysis; Decitabine; Female; Follow-Up Studies; Humans; Male; Metaphase; Middle Aged; Monosomy; Myelodysplastic Syndromes | 2006 |
31 other study(ies) available for azacitidine and Chromosome Deletion
| Article | Year |
|---|---|
Single cell T cell landscape and T cell receptor repertoire profiling of AML in context of PD-1 blockade therapy.
Topics: Aged; Aged, 80 and over; Azacitidine; Bone Marrow; CD8-Positive T-Lymphocytes; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Resistance, Neoplasm; Granzymes; Humans; Immune Checkpoint Inhibitors; Leukemia, Myeloid, Acute; Middle Aged; Nivolumab; Programmed Cell Death 1 Receptor; Receptors, Antigen, T-Cell; Single-Cell Analysis; T-Lymphocyte Subsets; T-Lymphocytes; Transcriptome | 2021 |
Noonan syndrome-associated myeloproliferative disorder with somatically acquired monosomy 7: impact on clinical decision making.
Topics: Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Clinical Decision-Making; DNA Methylation; Humans; Infant; Infant, Newborn; Male; Myeloproliferative Disorders; Noonan Syndrome | 2019 |
Reduction of Extramedullary Complications in Patients With Acute Myeloid Leukemia/Myelodysplastic Syndrome Treated With Azacitidine.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Shwachman-Diamond Syndrome | 2020 |
Myelodysplastic syndromes in a pediatric patient with Cri du Chat syndrome with a ring chromosome 5.
Topics: Adolescent; Age Factors; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cri-du-Chat Syndrome; Cytogenetic Analysis; Female; Humans; Myelodysplastic Syndromes; Quality of Life; Ring Chromosomes; Treatment Outcome | 2020 |
Pancytopenia, eosinophilia and coagulation disorders in a patient with T-acute lymphoblastic leukemia in prolonged remission.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers, Tumor; Blood Cell Count; Bone Marrow; Cancer Survivors; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 7; Diagnosis, Differential; Eosinophilia; Hemorrhagic Disorders; Humans; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Myelodysplastic Syndromes; Neoplasms, Second Primary; Pancytopenia; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Staurosporine; Tryptases | 2021 |
Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents.
Topics: Aged; Aged, 80 and over; Anemia; Antilymphocyte Serum; Antineoplastic Agents; Arsenic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Cyclosporine; Cytarabine; Decitabine; Disease Progression; Enzyme Inhibitors; Erythrocyte Transfusion; Female; Hematinics; Humans; Hydroxyurea; Immunologic Factors; Lenalidomide; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Survival Rate; Thalidomide; Treatment Failure; Tretinoin; Valproic Acid | 2017 |
Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Biomarkers, Tumor; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 17; Chromosomes, Human, Pair 21; Chromosomes, Human, Pair 5; Disease Progression; Female; Humans; In Situ Hybridization, Fluorescence; Janus Kinase 2; Leukemia, Myeloid, Acute; Multiple Myeloma; Mutation, Missense; Neoplasms, Multiple Primary; Remission Induction; Translocation, Genetic | 2017 |
Sustained remission with azacitidine monotherapy and an aberrant precursor B-lymphoblast population in juvenile myelomonocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 7; Humans; Infant; Leukemia, Myelomonocytic, Juvenile; Male; Precursor Cells, B-Lymphoid; Remission Induction | 2019 |
Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia.
Topics: Aged; Anemia, Macrocytic; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Drug Administration Schedule; Fatal Outcome; Female; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thrombocythemia, Essential; Treatment Outcome | 2013 |
Higher-risk myelodysplastic syndromes with del(5q): is sequential azacitidine-lenalidomide combination the way to go?
Topics: Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thalidomide | 2013 |
[Effectiveness of azacitidine in chronic myelomonocytic leukemia harboring del(20q) - a case report].
Topics: Aged; Antimetabolites, Antineoplastic; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 20; Humans; Leukemia, Myelomonocytic, Chronic; Male; Treatment Outcome | 2014 |
Identification of HERC5 and its potential role in NSCLC progression.
Topics: Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 4; Decitabine; DNA Copy Number Variations; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Promoter Regions, Genetic; Survival Analysis | 2015 |
Loss of response to azacitidine is associated with deletion 12p13 in a patient with myelodysplastic syndrome with unique translocation t(13;17)(q12;q25) after prior breast cancer and acute promyelocytic leukemia.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Chromosome Deletion; Chromosomes, Human, Pair 12; Chromosomes, Human, Pair 13; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Promyelocytic, Acute; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Translocation, Genetic | 2015 |
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation | 2016 |
A paediatric case of successful non-myeloablative bone marrow transplantation after azacitidine therapy for non-Down syndrome acute megakaryoblastic leukaemia with monosomy 7.
Topics: Adolescent; Antimetabolites, Antineoplastic; Azacitidine; Bone Marrow Transplantation; Chromosome Deletion; Chromosomes, Human, Pair 7; Combined Modality Therapy; Humans; Leukemia, Megakaryoblastic, Acute; Male | 2016 |
Perturbed hematopoietic stem and progenitor cell hierarchy in myelodysplastic syndromes patients with monosomy 7 as the sole cytogenetic abnormality.
Topics: Antigens, CD; Azacitidine; Biomarkers; Cell Differentiation; Cell Lineage; Chromosome Deletion; Chromosomes, Human, Pair 7; Female; Flow Cytometry; Hematopoietic Stem Cells; High-Throughput Nucleotide Sequencing; Humans; Immunophenotyping; In Situ Hybridization, Fluorescence; Male; Mutation; Myelodysplastic Syndromes | 2016 |
Alleviation of myelodysplastic syndrome-associated skin rush after treatment with decitabine.
Topics: Aged; Anemia, Refractory; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Y; Decitabine; Exanthema; Humans; Male | 2008 |
Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
Topics: Acute Disease; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Blood Transfusion; Chromosome Deletion; Chromosomes, Human, Pair 5; Decitabine; Humans; Lenalidomide; Leukemia, Myeloid; Male; Neoplasm Recurrence, Local; Remission Induction; Thalidomide | 2009 |
LARG at chromosome 11q23 has functional characteristics of a tumor suppressor in human breast and colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chromosome Deletion; Chromosome Mapping; Chromosomes, Human, Pair 11; Colorectal Neoplasms; Decitabine; DNA Methylation; Female; Guanine Nucleotide Exchange Factors; Humans; Hydroxamic Acids; Male; Nucleic Acid Hybridization; Promoter Regions, Genetic; Protein Synthesis Inhibitors; Rho Guanine Nucleotide Exchange Factors; Transfection; Tumor Suppressor Proteins | 2009 |
Caution using hypomethylating agents in myelodysplasia or myeloid leukemia with complex cytogenetics.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Blast Crisis; Chromosome Deletion; Female; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes | 2010 |
Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine.
Topics: Antimetabolites; Azacitidine; Chromosome Deletion; Chromosomes, Human, Pair 5; Chromosomes, Human, Pair 7; Compassionate Use Trials; Follow-Up Studies; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Karyotyping; Monosomy; Myelodysplastic Syndromes; Prognosis; Proportional Hazards Models; Treatment Outcome | 2011 |
TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antimetabolites; Azacitidine; Bone Marrow Cells; Chromosome Deletion; Chromosomes, Human, Pair 5; Disease Progression; Female; Follow-Up Studies; Genes, p53; Humans; Incidence; Kaplan-Meier Estimate; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Prognosis; Risk; Treatment Outcome; Young Adult | 2013 |
High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene.
Topics: Adolescent; Antineoplastic Agents; Azacitidine; Base Sequence; Cell Differentiation; Cell Line; Cell Line, Tumor; Child; Child, Preschool; Chromosome Breakage; Chromosome Deletion; Chromosomes, Human, Pair 3; CpG Islands; Decitabine; DNA Methylation; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Infant; Membrane Glycoproteins; Molecular Sequence Data; Neuroblastoma; Nucleic Acid Hybridization; Reverse Transcriptase Polymerase Chain Reaction; Semaphorins; Tretinoin | 2007 |
Genetic and epigenetic changes in the common 1p36 deletion in neuroblastoma tumours.
Topics: Adaptor Proteins, Signal Transducing; Azacitidine; Cell Line, Tumor; Chromosome Deletion; Chromosomes, Human, Pair 1; Class I Phosphatidylinositol 3-Kinases; Decitabine; DNA Methylation; DNA Mutational Analysis; DNA-Binding Proteins; DNA, Neoplasm; Exons; Genetic Variation; Histones; Humans; Hydroxamic Acids; Mutation; Neuroblastoma; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Retinol-Binding Proteins, Cellular; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2007 |
Abnormal expression of vimentin intermediate filaments in human lymphoid cell lines with deletion or translocation of the distal end of chromosome 8.
Topics: Azacitidine; Burkitt Lymphoma; Cell Line; Chromosome Deletion; Chromosomes, Human, 6-12 and X; Fluorescent Antibody Technique; Humans; Intermediate Filament Proteins; Lymphocytes; Translocation, Genetic; Vimentin | 1984 |
Persistence of increased levels of ribosomal gene activity in CHO-K1 cells treated in vitro with demethylating agents.
Topics: Animals; Antimetabolites; Azacitidine; CHO Cells; Chromosome Deletion; Clone Cells; Cricetinae; DNA, Ribosomal; Ethionine; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Methylation; Mitotic Index; Mutagens; Nucleolus Organizer Region; Silver Staining | 1995 |
Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer.
Topics: Aged; Azacitidine; Carrier Proteins; Chromosome Deletion; Cyclin-Dependent Kinase Inhibitor p16; Decitabine; DNA Methylation; DNA Modification Methylases; DNA Mutational Analysis; DNA, Neoplasm; Gene Expression; Heterozygote; Humans; Male; Middle Aged; Neoplasm Metastasis; Polymerase Chain Reaction; Prostatic Neoplasms; Sequence Analysis, DNA; Tumor Cells, Cultured | 1997 |
Preferential induction of chromosome 1 multibranched figures and whole-arm deletions in a human pro-B cell line treated with 5-azacytidine or 5-azadeoxycytidine.
Topics: Antimetabolites, Antineoplastic; Azacitidine; B-Lymphocytes; Cell Line; Centromere; Chromosome Deletion; Chromosomes, Human, Pair 1; Decitabine; Gene Rearrangement; Hematopoietic Stem Cells; Humans; Time Factors | 1997 |
Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Carcinoma; Chromosome Deletion; Chromosomes, Human, Pair 17; Cohort Studies; Decitabine; DNA Methylation; Enzyme Inhibitors; Female; Follow-Up Studies; Gene Deletion; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, p53; Humans; Kruppel-Like Transcription Factors; Loss of Heterozygosity; Neoplasm Proteins; Prognosis; Prospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Survival Analysis; Transcription Factors; Tumor Cells, Cultured | 2001 |
Petunia plants escape from negative selection against a transgene by silencing the foreign DNA via methylation.
Topics: Agrobacterium tumefaciens; Amidohydrolases; Azacitidine; Blotting, Southern; Cell Line; Chromosome Deletion; Cloning, Molecular; DNA Transposable Elements; DNA, Bacterial; Gene Expression Regulation, Enzymologic; Methylation; Nucleic Acid Hybridization; Phenotype; Plants, Genetically Modified; Restriction Mapping; Selection, Genetic; Transformation, Genetic | 1992 |
5-Azacytidine induces sex chromosome loss and interchange in immature germ cells of Drosophila mei-9 males.
Topics: Animals; Azacitidine; Chromosome Deletion; Drosophila melanogaster; Male; Meiosis; Mutagens; Sex Chromosomes; Spermatozoa; Y Chromosome | 1989 |